Cystic Fibrosis is caused by mutations in the CFTR gene (Cystic Fibrosis Transmembrane conductance Regulator) on chromosome 7. The CFTR protein is a chloride channel in epithelial cell membranes.
Dysfunction leads to: defective chloride and bicarbonate transport → dehydrated airway surface liquid → thick, viscous mucus → obstruction, inflammation, infection.
Autosomal recessive inheritance: Two mutated copies required for disease. Carriers (one copy) are unaffected. Incidence approximately 1:2,500 live births in Caucasian populations.
CF produces an obstructive pattern — reduced FEV1/FVC ratio, air trapping, hyperinflation. FEV1 % predicted is the key prognostic marker.
Lung transplant listing: Consider when FEV1 <30%, rapid decline, increasing hospitalisations, haemoptysis, or respiratory failure.
Consanguineous marriages (first-cousin unions) are more prevalent across Arab populations — GCC rates range from 30–60% in some communities. This significantly increases the risk of autosomal recessive conditions including CF. Saudi Arabia and UAE have reported rising CF diagnosis rates partly attributable to expanded neonatal screening programmes.
Saudi Arabia has a national neonatal screening programme (MNSP) covering multiple metabolic and genetic conditions including CF. The UAE has expanded heel-prick screening. Qatar (HMC) and Kuwait have specialist CF clinics. Carrier testing and genetic counselling are increasingly available but uptake varies.
The primary goal of airway clearance therapy (ACT) is to mobilise and expectorate thick, viscous mucus from the bronchial tree, reducing infection risk and preserving lung function. ACT is a lifelong, daily commitment in CF — non-adherence is associated with accelerated lung function decline.
Minimum frequency: Twice daily (BD) physiotherapy when well. Increase to four times daily (QID) during pulmonary exacerbations.
ACBT is the most widely used airway clearance technique — evidence-based, requires no equipment, adaptable to all ages. Comprises three phases repeated cyclically.
Relaxed, gentle tidal breathing at normal rate and depth. Allows airways to recover, prevents bronchoconstriction. 5–10 breaths between active phases.
Deep, controlled inspirations with 3-second hold at full inspiration — loosens and mobilises peripheral secretions. 3–5 deep breaths.
One or two "huffs" — forced expirations with open glottis (say "huff"). High-volume huff moves secretions from periphery; low-volume huff expectorates from central airways. Follow with breathing control.
Oscillating positive expiratory pressure (OPEP) devices combine airway pressure with vibration — mobilise secretions independently. Suitable for self-treatment at home.
Nurse tip: Devices must be cleaned and dried thoroughly after each use. Colonised patients should not share devices — strict personal equipment policy.
High-frequency chest wall oscillation (HFCWO) — inflatable vest (ThAIRapy / The Vest) delivers rapid oscillations to the chest wall, loosening secretions throughout the lungs. Particularly useful for:
Frequency 10–20 Hz, pressure 5–20 cmH2O — adjusted by physiotherapist. Sessions 20–30 minutes. Intersperse with huff/cough every few minutes to expectorate mobilised secretions.
Sequencing principle: Mucoactive agents are given before physiotherapy to maximise their effect — they loosen mucus so ACT can clear it effectively.
Recombinant human DNase — cleaves extracellular DNA released from neutrophils in CF sputum, dramatically reducing viscosity. Give 30 minutes before physiotherapy. 2.5 mg daily via jet nebuliser.
Osmotically draws water onto the airway surface, rehydrates mucus, restores mucociliary clearance. Give before physiotherapy. Pre-medicate with bronchodilator (salbutamol) to prevent bronchoconstriction. 4 mL via ultrasonic or mesh nebuliser.
Post bilateral lung transplant, native CF airway disease is eliminated but ACT remains important to manage secretions from the transplanted lungs (no innate mucociliary clearance initially). Modified ACBT is used — avoid high-pressure techniques early post-operatively that could compromise surgical anastomoses.
Immunosuppression post-transplant radically changes infection risk. Strict hand hygiene and respiratory precautions. Personal physiotherapy equipment only. No cross-contamination with non-transplant CF patients. Burkholderia cepacia — absolute contraindication to transplant listing in most centres.
| Organism | Stage | Clinical Significance | Management Approach |
|---|---|---|---|
| Staphylococcus aureus (incl. MRSA) |
Early | Common early pathogen, childhood. MRSA associated with worse outcomes. | Flucloxacillin prophylaxis (controversial). MRSA — isolation, rifampicin/fusidic acid combinations. |
| Haemophilus influenzae | Early | Common in early CF, contributes to exacerbations in children and young adults. | Amoxicillin/co-amoxiclav. Prophylaxis not routinely used. |
| Pseudomonas aeruginosa | Chronic | Dominant pathogen in adults. Chronic colonisation — impossible to eradicate once established. Major driver of lung function decline. | New infection: eradication protocol. Chronic: alternating inhaled antibiotics monthly. |
| Burkholderia cepacia complex | Late / Terminal | Multiple genomovars (B. multivorans, B. cenocepacia). Associated with rapid fatal decline ("cepacia syndrome"). B. cenocepacia most virulent. | Most stringent isolation. IV antibiotics (meropenem combinations). Contraindication to transplant in most centres. |
| Non-tuberculous mycobacteria (NTM) | Variable | MAC, M. abscessus — increasing in prevalence. M. abscessus difficult to treat, significant pre-transplant concern. | Multi-drug regimens (macrolides, aminoglycosides, rifampicin). Specialist decision. |
| Aspergillus fumigatus | Any stage | Allergic bronchopulmonary aspergillosis (ABPA) in ~5–10% of CF. Causes additional airway inflammation and bronchiectasis. | Oral prednisolone + itraconazole/voriconazole. Monitor IgE, eosinophils. |
New Pseudomonas detection: Act early — eradication is possible in first isolation. Once chronic colonisation established, eradication is not achievable.
Alternating monthly inhaled antibiotics to suppress bacterial load:
Alternatives: Aztreonam lysine (Cayston), Colistimethate sodium (Promixin, Colobreathe). Rotating agents may reduce resistance development.
Two-drug combination required — synergy and reduces resistance
Beta-lactam: Piperacillin/tazobactam or Ceftazidime or Meropenem
+ Aminoglycoside: Tobramycin (once-daily dosing preferred) or Amikacin
Always base IV antibiotics on most recent sputum sensitivities. CF patients accumulate resistance patterns — never empirical without culture history review.
Typically 14 days IV antibiotics. Review at 7 days — extend if inadequate response. Home IV (OPAT) increasingly used with PICC line.
NEVER mix patients with different CF pathogens — particularly:
Contact precautions — gown and gloves. Single room. Decolonisation protocol as per local policy.
Regular flushing per protocol. Monitor insertion site for infection. Weekly dressing changes minimum. Document line position. Nurse-led PICC care education for home IV patients — increasingly common in GCC tertiary centres.
85% of CF patients have exocrine pancreatic insufficiency — absent or insufficient digestive enzymes → fat malabsorption → steatorrhoea → failure to thrive.
Creon (pancreatin — lipase, amylase, protease) is taken with every meal and snack containing fat. Dose is titrated to achieve normal stool consistency and growth.
Fibrosing colonopathy risk with high-dose PERT — never exceed maximum dose. Symptoms: abdominal pain, obstruction, blood PR.
CF patients require 120–150% of normal caloric needs due to malabsorption, increased work of breathing, chronic infection-driven hypermetabolism, and impaired nutrient absorption.
Fat malabsorption leads to deficiency of vitamins A, D, E, K. CF-specific multivitamin supplements (e.g., ADEK vitamins) must be given daily.
CFRD is a unique form of diabetes — distinct from Type 1 and Type 2. Results from progressive loss of beta and alpha cells as pancreatic fibrosis advances, combined with insulin resistance during illness.
Ramadan fasting (GCC context): Requires individualised insulin adjustment plan, regular glucose monitoring, and agreement with CF physician and Imam guidance where needed. Fasting carries significant risk in CFRD — early medical discussion essential.
Partial or complete obstruction of the ileocaecum from thick, inspissated faecal material — unique to CF. Often presents with right iliac fossa pain, distension, vomiting, and reduced stool frequency.
CF sweat is excessively salty. In GCC heat (>40°C), CF patients lose large amounts of sodium chloride through sweating — risk of hyponatraemia, dehydration, and heat exhaustion.
CFTR modulators are small molecules that target the underlying CFTR protein defect — not just the downstream consequences. They represent the most significant therapeutic advance in CF history.
Increase the probability that the CFTR channel opens — target Class III (gating) mutations. Example: Ivacaftor
Help misfolded CFTR protein traffic to the cell surface — target Class II (processing) mutations like F508del. Examples: Lumacaftor, Tezacaftor, Elexacaftor
First approved modulator. Significant improvement in FEV1 (+10% absolute), sweat chloride reduction, weight gain, quality of life — in patients with gating mutations.
Minimal benefit in F508del homozygous patients (protein does not reach surface — potentiating an absent protein has no effect).
First modulator for the most common CF genotype. Modest improvement in FEV1 (+2–3% absolute), modest reduction in exacerbations. Significant drug interactions — induces CYP3A, reducing many drugs including ivacaftor itself.
Side effects: chest tightness (first dose — pre-treat with bronchodilator), elevated LFTs.
Breakthrough therapy: Elexacaftor/Tezacaftor/Ivacaftor (ETI) has transformed CF management — eligible for >85% of CF patients (anyone with at least one F508del allele). Approved from age 2+ in many countries.
Triple combination: two correctors (elexacaftor + tezacaftor) + one potentiator (ivacaftor). Elexacaftor binds a different site on CFTR than tezacaftor — additive corrective effect.
Bilateral sequential lung transplantation (BSLT) — both lungs replaced. CF-specific airway microbiome makes single lung transplant unsuitable (cross-contamination). ETI has significantly reduced transplant numbers since 2019.
Burkholderia cenocepacia: Absolute contraindication to lung transplant listing in most centres — associated with rapidly fatal post-transplant cepacia syndrome.
Non-viral gene therapy (mRNA, lipid nanoparticle delivery, lentiviral vectors) in clinical trials. Targeting the 15% of CF patients not eligible for CFTR modulators (Class I stop-codon mutations). UK CF Gene Therapy Consortium leading trials.
Ataluren — promotes ribosomal read-through of premature stop codons, enabling some protein production. Limited to nonsense mutations. Under regulatory review.
Hydroxychloroquine, azithromycin (immunomodulatory dose), anti-IL-8 and anti-IL-17 agents in trials — targeting CF lung inflammation independent of CFTR function.
Bacteriophage cocktails targeting multidrug-resistant CF pathogens (P. aeruginosa, M. abscessus) — compassionate use cases, clinical trials ongoing.
At least ONE of the following clinical features:
PLUS at least ONE evidence of CFTR dysfunction:
| Organism | Stage | Tx Approach | Isolation Level |
|---|---|---|---|
| S. aureus / H. influenzae | Early (childhood) | Oral antibiotics, flucloxacillin | Standard |
| Pseudomonas aeruginosa (new) | Mid — eradicate | Inhaled tobramycin + oral ciprofloxacin ×28d | Cohort segregation |
| Pseudomonas aeruginosa (chronic) | Mid–late — suppress | Alternating monthly inhaled antibiotics | Separate from non-colonised |
| Burkholderia cepacia complex | Late | IV meropenem combinations, specialist | Strictest — single room, no transplant* |
| NTM (M. abscessus) | Variable | Multi-drug regimens, specialist decision | Contact precautions |
* B. cenocepacia is an absolute contraindication to lung transplant in most CF centres.
| Drug | Brand | Mechanism | Target Mutation | Notes |
|---|---|---|---|---|
| Ivacaftor | Kalydeco | Potentiator | G551D & other gating (Class III) | Significant benefit; minority of CF patients |
| Lumacaftor/Ivacaftor | Orkambi | Corrector + Potentiator | F508del homozygous | Moderate benefit; CYP3A inducer — drug interactions |
| Tezacaftor/Ivacaftor | Symdeko/Symkevi | Corrector + Potentiator | F508del (homo & hetero) | Better tolerated than Orkambi; superseded by Kaftrio |
| Elexacaftor/Tezacaftor/Ivacaftor | Kaftrio/Trikafta | 2 Correctors + Potentiator | ≥1 copy F508del | Breakthrough — >85% eligible; FEV1 +14%; transformative |